Fampridine
▶H 2 receptor antagonists(cimetidine)increase the concentration
offampridine. Avoid.rTheoretical
Febuxostat
▶Febuxostatis predicted to increase the exposure to
azathioprine. Avoid.rTheoretical
▶Febuxostatis predicted to increase the exposure todidanosine.
rTheoretical
▶Febuxostatis predicted to increase the exposure to
mercaptopurine. Avoid.rTheoretical
Felbinac→see NSAIDs
Felodipine→see calcium channel blockers
Fenofibrate→see fibrates
Fenoprofen→see NSAIDs
Fentanyl→see opioids
Ferric carboxymaltose→see iron (injectable)
Ferric maltol→see iron (oral)
Ferrous fumarate→see iron (oral)
Ferrous gluconate→see iron (oral)
Ferrous sulfate→see iron (oral)
Fesoterodine→seeTABLE 10p. 849 (antimuscarinics)
▶Antiarrhythmics(dronedarone)are predicted to increase the
exposure tofesoterodine. Adjustfesoterodinedose with
moderate inhibitors of CYP3A4 in hepatic and renal
impairment.nStudy
▶Antiepileptics(carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone)are predicted to decrease the exposure
tofesoterodine. Avoid.oStudy
▶Antifungals, azoles(fluconazole, isavuconazole, posaconazole)
are predicted to increase the exposure tofesoterodine. Adjust
fesoterodinedose with moderate inhibitors of CYP3A4 in
hepatic and renal impairment.nStudy
▶Antifungals, azoles(itraconazole, ketoconazole, voriconazole)are
predicted to moderately increase the exposure tofesoterodine.
Adjustfesoterodinedose with potent inhibitors of CYP3A4;
avoid in hepatic and renal impairment.rStudy
▶Aprepitantis predicted to increase the exposure to
fesoterodine. Adjustfesoterodinedose with moderate
inhibitors of CYP3A4 in hepatic and renal impairment.n
Study
▶Calcium channel blockers(diltiazem, verapamil)are predicted to
increase the exposure tofesoterodine. Adjustfesoterodine
dose with moderate inhibitors of CYP3A4 in hepatic and renal
impairment.nStudy
▶Cobicistatis predicted to moderately increase the exposure to
fesoterodine. Adjustfesoterodinedose with potent inhibitors
of CYP3A4; avoid in hepatic and renal impairment.r
Study
▶Crizotinibis predicted to increase the exposure to
fesoterodine. Adjustfesoterodinedose with moderate
inhibitors of CYP3A4 in hepatic and renal impairment.n
Study
▶Enzalutamideis predicted to decrease the exposure to
fesoterodine. Avoid.oStudy
▶HIV-protease inhibitorsare predicted to moderately increase
the exposure tofesoterodine. Adjustfesoterodinedose with
potent inhibitors of CYP3A4; avoid in hepatic and renal
impairment.rStudy
▶Idelalisibis predicted to moderately increase the exposure to
fesoterodine. Adjustfesoterodinedose with potent inhibitors
of CYP3A4; avoid in hepatic and renal impairment.r
Study
▶Imatinibis predicted to increase the exposure tofesoterodine.
Adjustfesoterodinedose with moderate inhibitors of CYP3A4
in hepatic and renal impairment.nStudy
▶Macrolides(clarithromycin)are predicted to moderately
increase the exposure tofesoterodine. Adjustfesoterodine
dose with potent inhibitors of CYP3A4; avoid in hepatic and
renal impairment.rStudy
▶Macrolides(erythromycin)are predicted to increase the
exposure tofesoterodine. Adjustfesoterodinedose with
moderate inhibitors of CYP3A4 in hepatic and renal
impairment.nStudy
▶Mitotaneis predicted to decrease the exposure tofesoterodine.
Avoid.oStudy▶Netupitantis predicted to increase the exposure to
fesoterodine. Adjustfesoterodinedose with moderate
inhibitors of CYP3A4 in hepatic and renal impairment.n
Study
▶Nilotinibis predicted to increase the exposure tofesoterodine.
Adjustfesoterodinedose with moderate inhibitors of CYP3A4
in hepatic and renal impairment.nStudy
▶Rifampicinis predicted to decrease the exposure to
fesoterodine. Avoid.oStudy
▶St John’s Wortis predicted to decrease the exposure to
fesoterodine. Avoid.rTheoretical
Fexofenadine→see antihistamines, non-sedating
Fibrates
bezafibrate.ciprofibrate.fenofibrate.gemfibrozil..
▶Antacidsslightly to moderately decrease the exposure to
gemfibrozil.oStudy
▶Bezafibrateis predicted to increase the risk of nephrotoxicity
when given withciclosporin.rTheoretical
▶Fenofibrateincreases the risk of nephrotoxicity when given
withciclosporin.rStudy
▶Colchicineincreases the risk of rhabdomyolysis when given
withfibrates.rAnecdotal
▶Fibratesare predicted to increase the anticoagulant effect of
coumarins. Monitor INR and adjust dose.rStudy
▶Gemfibrozilis predicted to increase the exposure to
dabrafenib.oTheoretical
▶Fibratesare predicted to increase the risk of rhabdomyolysis
when given withdaptomycin.rTheoretical
▶Gemfibrozilvery markedly increases the exposure to
dasabuvir. Avoid.rStudy
▶Gemfibrozilis predicted to increase the exposure to
eluxadoline. Avoid.oTheoretical
▶Gemfibrozilmoderately increases the exposure to
enzalutamide. Avoid or adjustenzalutamidedose.rStudy
▶Fibratesare predicted to increase the risk of gallstones when
given withezetimibe.rTheoretical
▶Fibratesare predicted to increase the risk of hypoglycaemia
when given withinsulins.oTheoretical
▶Gemfibrozilis predicted to moderately increase the exposure
tomontelukast.oStudy
▶Fibratesare predicted to increase the anticoagulant effect of
phenindione. Monitor INR and adjust dose.rStudy
▶Gemfibrozilincreases the exposure topioglitazone. Monitor
blood glucose and adjust dose.rStudy
▶Gemfibrozilincreases the exposure torepaglinide. Avoid.
rStudy
▶Gemfibrozilis predicted to increase the exposure toretinoids
(alitretinoin). Adjustalitretinoindose.oTheoretical
▶Gemfibrozilincreases the concentration ofretinoids
(bexarotene). Avoid.rStudy
▶Gemfibrozilincreases the exposure toselexipag. Avoid.r
Study
▶Ciprofibrateincreases the risk of rhabdomyolysis when given
withstatins(atorvastatin). Avoid or adjust dose.rStudy
▶Bezafibrateincreases the risk of rhabdomyolysis when given
withstatins(atorvastatin, fluvastatin).rStudy
▶Fenofibrateincreases the risk of rhabdomyolysis when given
withstatins(atorvastatin, simvastatin). Adjustfenofibratedose,
p. 131.rAnecdotal
▶Ciprofibrateincreases the risk of rhabdomyolysis when given
withstatins(fluvastatin).rStudy
▶Fenofibrateis predicted to increase the risk of rhabdomyolysis
when given withstatins(fluvastatin). Adjustfenofibratedose,
p. 131.rTheoretical
▶Fenofibrateis predicted to increase the risk of rhabdomyolysis
when given withstatins(pravastatin). Avoid.rTheoretical
▶Fibrates(bezafibrate, ciprofibrate)increase the risk of
rhabdomyolysis when given withstatins(pravastatin). Avoid.
rStudy
▶Fenofibrateincreases the risk of rhabdomyolysis when given
withstatins(rosuvastatin). Adjustfenofibrateandrosuvastatin
doses,p. 131, p. 133.rAnecdotal
▶Fibrates(bezafibrate, ciprofibrate)increase the risk of
rhabdomyolysis when given withstatins(rosuvastatin). Adjust
rosuvastatindose,p. 133.rStudy922 Fampridine—Fibrates BNFC 2018 – 2019
Interactions|Appendix 1A1